REYON Pharmaceutical Crecimiento futuro
Future controles de criterios 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for REYON Pharmaceutical.
Información clave
n/a
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 38.2% |
| Tasa de crecimiento de los ingresos | n/a |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | None |
| Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
No hay actualizaciones
Recent updates
REYON Pharmaceutical Co., Ltd.'s (KRX:102460) Shareholders Might Be Looking For Exit
Oct 18
There May Be Reason For Hope In REYON Pharmaceutical's (KRX:102460) Disappointing Earnings
Mar 31Consider This Before Buying REYON Pharmaceutical Co., Ltd. (KRX:102460) For The 1.6% Dividend
May 08Here's Why REYON Pharmaceutical (KRX:102460) Has A Meaningful Debt Burden
Apr 09What Percentage Of REYON Pharmaceutical Co., Ltd. (KRX:102460) Shares Do Insiders Own?
Feb 28Read This Before Buying REYON Pharmaceutical Co., Ltd. (KRX:102460) For Its Dividend
Jan 20
REYON Pharmaceutical (KRX:102460) Seems To Use Debt Quite Sensibly
Jan 02Did REYON Pharmaceutical's (KRX:102460) Share Price Deserve to Gain 50%?
Dec 12How Much Of REYON Pharmaceutical Co., Ltd. (KRX:102460) Do Insiders Own?
Nov 24En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como REYON Pharmaceutical no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.
Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.
Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 6/30/2024 | 148,991 | -104 | -22,225 | 2,657 | N/A |
| 3/31/2024 | 151,056 | 1,902 | -20,609 | 4,252 | N/A |
| 12/31/2023 | 151,071 | 3,583 | -20,227 | 8,645 | N/A |
| 9/30/2023 | 150,584 | 8,456 | -19,038 | 12,971 | N/A |
| 6/30/2023 | 152,043 | 10,614 | -21,686 | 12,848 | N/A |
| 3/31/2023 | 153,907 | 7,503 | -32,911 | 9,962 | N/A |
| 12/31/2022 | 154,039 | 7,359 | -54,404 | 8,729 | N/A |
| 9/30/2022 | 152,549 | 4,816 | -63,949 | 9,463 | N/A |
| 6/30/2022 | 150,237 | 2,774 | -82,042 | 12,848 | N/A |
| 3/31/2022 | 146,329 | 6,265 | -103,331 | 15,345 | N/A |
| 12/31/2021 | 142,801 | 5,412 | -105,312 | 11,685 | N/A |
| 9/30/2021 | 139,414 | 5,650 | -107,713 | 8,450 | N/A |
| 6/30/2021 | 135,893 | 6,518 | -93,909 | 5,607 | N/A |
| 3/31/2021 | 131,303 | 4,843 | -70,265 | 2,981 | N/A |
| 12/31/2020 | 130,034 | 3,844 | -47,287 | 4,599 | N/A |
| 9/30/2020 | 129,738 | 1,720 | -39,699 | 2,314 | N/A |
| 6/30/2020 | 129,684 | 2,165 | -35,337 | 6,798 | N/A |
| 3/31/2020 | 131,581 | 2,165 | -53,806 | -12,825 | N/A |
| 12/31/2019 | 131,558 | 4,946 | -63,564 | -12,184 | N/A |
| 9/30/2019 | 128,267 | 1,478 | -56,438 | -5,595 | N/A |
| 6/30/2019 | 125,963 | 594 | -74,593 | -12,861 | N/A |
| 3/31/2019 | 124,192 | 3,299 | -47,790 | 5,730 | N/A |
| 12/31/2018 | 122,990 | 1,343 | -27,748 | 11,449 | N/A |
| 9/30/2018 | 122,850 | 7,021 | -25,025 | 8,456 | N/A |
| 6/30/2018 | 123,936 | 9,643 | 2,584 | 11,159 | N/A |
| 3/31/2018 | 124,150 | 9,073 | N/A | 15,186 | N/A |
| 12/31/2017 | 126,253 | 12,887 | N/A | 16,764 | N/A |
| 9/30/2017 | 126,748 | 13,195 | N/A | 14,348 | N/A |
| 12/31/2016 | 121,847 | 10,701 | N/A | 9,471 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Insufficient data to determine if A102460's forecast earnings growth is above the savings rate (2.6%).
Beneficios vs. Mercado: Insufficient data to determine if A102460's earnings are forecast to grow faster than the KR market
Beneficios de alto crecimiento: Insufficient data to determine if A102460's earnings are expected to grow significantly over the next 3 years.
Ingresos vs. Mercado: Insufficient data to determine if A102460's revenue is forecast to grow faster than the KR market.
Ingresos de alto crecimiento: Insufficient data to determine if A102460's revenue is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if A102460's Return on Equity is forecast to be high in 3 years time